Recent studies demonstrated that metformin-induced activation of AMPK disrupts the crosstalk between insulin/IGF-1 receptor and G protein-coupled receptor signaling pathways in pancreatic cancer cells and inhibits proliferation of these cells in xenograft models, suggesting this crosstalk as a target for treatment of pancreatic cancer by metformin [28]. This evidence concerns the gene INS and familial pancreatic carcinoma.